The trial, known as the Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS (PARTNERS), began enrolling patients on Thursday, WHO said in a statement.
This source provides a summary via RSS.
Continue reading the complete report from the original publisher.
Read Full Story
